Tratamento cirúrgico das valvopatias: parte 1

Braile, Domingo Marcolino; Volpe, M; Ramin, Serginando L; Souza, Dorotéia Rossi Silva

doi:10.1590/s0102-76381994000200007

Cited by 4 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bovine pericardial bioprostheses were introduced by Ionesco, aiming at improving the durability and hemodynamical performance compared to porcine aortic valve bioprostheses [8,9]. Initial tests in a pulse simulator identified the possibility of early structural failure [10], but changes in the project and in the technique of tissue preparation gave favorable hemodynamic and clinical results [11,12].…”

Section: Introductionmentioning

confidence: 99%

Bioprótese valvar de pericárdio bovino St Jude Medical-Biocor: sobrevida tardia

Bacco¹,

Sant'Anna²,

Sant’Anna³

et al. 2005

Rev Bras Cir Cardiovasc

View full text Add to dashboard Cite

Methods: From 1992 to 2000, 304 patients were discharged from hospital after bioprosthesis implantation. Ages ranged from 15 to 83 years (mean: 60.6 ± ± ± ± ± 14.3 years) and 50.3% were male. Patient deaths and events related to bioprosthesis (infection, thromboembolism and structural failure) were considered for estimation of cumulative probability of survival and event-free survival.Results: Total follow-up was 931.0 patients-year. During follow-up there were 28 (9.2%) deaths. Causes were bioprosthesis failure in five (1.6%), cardiac in seven (2.3%), non-cardiac in four (1.3%), and unknown in 12 (3.9%) patients. Events related to bioprosthesis were: endocarditis: 18 (5.9%), fibrocalcific degeneration: 15 (4.9%), thromboembolism: three (1.0%), hemolysis: one (0.3%). Bioprosthesis dysfunctions resulted in 16 (5.2%) reoperations due to fibrocalcific degeneration (nine), endocarditis (six) and thromboembolism (one). Probability of survival was higher in the young population (< 40 years, n=35) when compared to the older group (> 60 year, n=187): 82.0 ± ± ± ± ± 13.3% vs. 58.8 ± ± ± ± ± 13.6% in the 9 th year. Event-free survival was 77.5 ± ± ± ± ± 3.7% for 5 th year and 40.2 ± ± ± ± ± 9.0% for 10 th year. 424BACCO, FW ET AL -St Jude Medical-Biocor bovine pericardial bioprosthesis: long-term survival Braz J Cardiovasc Surg 2005; 20(4): 423-431 Resultados: Em um seguimento total de 931,0 pacientesano, ocorreram 28 (9,2%) óbitos tardios, sendo cinco (1,6%) relacionados à bioprótese, sete (2,3%) cardíacos, quatro (1,3%) não-cardíacos e 12 (3,9%)

show abstract

Section: Introductionmentioning

confidence: 99%

Bioprótese valvar de pericárdio bovino St Jude Medical-Biocor: sobrevida tardia

Bacco¹,

Sant'Anna²,

Sant’Anna³

et al. 2005

Rev Bras Cir Cardiovasc

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

<![CDATA[St Jude Medical-Biocor bovine pericardial bioprosthesis: long-term survival]]>

Bacco¹,

Sant'anna²,

Sant’Anna³

et al. 2005

Braz. j. cardiovasc. surg.

View full text Add to dashboard Cite

The objective of this work is to present longterm results of valve replacement using SJM-Biocor TM bovine pericardial bioprostheses. Methods: From 1992 to 2000, 304 patients were discharged from hospital after bioprosthesis implantation. Ages ranged from 15 to 83 years (mean: 60.6 ± ± ± ± ± 14.3 years) and 50.3% were male. Patient deaths and events related to bioprosthesis (infection, thromboembolism and structural failure) were considered for estimation of cumulative probability of survival and event-free survival. Results: Total follow-up was 931.0 patients-year. During follow-up there were 28 (9.2%) deaths. Causes were bioprosthesis failure in five (1.6%), cardiac in seven (2.3%), non-cardiac in four (1.3%), and unknown in 12 (3.9%) patients. Events related to bioprosthesis were: endocarditis: 18 (5.9%), fibrocalcific degeneration: 15 (4.9%), thromboembolism: three (1.0%), hemolysis: one (0.3%). Bioprosthesis dysfunctions resulted in 16 (5.2%) reoperations due to fibrocalcific degeneration (nine), endocarditis (six) and thromboembolism (one). Probability of survival was higher in the young population (< 40 years, n=35) when compared to the older group (> 60 year, n=187): 82.0 ± ± ± ± ± 13.3% vs. 58.8 ± ± ± ± ± 13.6% in the 9 th year. Event-free survival was 77.5 ± ± ± ± ± 3.7% for 5 th year and 40.2 ± ± ± ± ± 9.0% for 10 th year. Overall estimative of structural failure for a SJM-Biocor TM was 5% in 5 th year increasing to 20% in the 10 th year. In the aortic position the values were zero and 8%, respectively. Considering current clinical conditions, 88.5% are in NYHA class I, 9.1% in class II and 2.3% in class III. Conclusions: SJM-Biocor TM bovine pericardial bioprostheses resulted in satisfactory survival of patients, related to low prevalence of bioprosthesis dysfunction. Descriptors: Bioprosthesis. Heart valve prosthesis. Heart valves. Resumo Objetivo: Nosso objetivo é apresentar resultados a longo prazo da subsituição valvar por bioprótese de pericárdio bovino SJM-Biocor TM. Método: Entre 1992 e 2000, tiveram alta hospitalar, após substituição valvar por bioprótese de pericárdio bovino SJM-Biocor TM 304 pacientes. Idades eram de 15 a 83 anos (média: 60,6± ± ± ± ±14,3), sendo 50,3% do sexo masculino. Pacientes tiveram situação clínica atualizada e análise atuarial foi empregada no cálculo da sobrevida simples e livre de eventos.

show abstract

“…Prosthesis diversity kept increasing, but patients with valve substituents started to experience complications, like fractures, wear and tear, thromboembolism, infection, hemolysis, rupture, and calcification, directly or indirectly associated with the prostheses [7][8][9] .…”

mentioning

confidence: 99%